Drug major Zydus Cadila has received final approval from the United States health regulator to market Liothyronine Sodium tablets that are used to treat underactive thyroid.

Cadila Healthcare said its statement in a regulatory filing which reads “Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Liothyronine Sodium tablets USP, 5 mcg, 25 mcg, and 50 mcg”. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad, the company added.

Notably, Liothyronine is a man-made form of thyroid hormone which is used to treat an underactive thyroid or hypothyroidism. It replaces or provides more thyroid hormone, which is normally made by the thyroid gland. Zydus Cadila is a part of the Cadila Healthcare group.

The group now has 312 approvals and has so far filed over 390 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

UK biz activity suffers steep fall in January: Report

'Covid deaths could surpass 600,000 in US': warns Biden

Brazil President thanks PM Modi for Covid vaccine dozes